Our Products

Our goal is to help people and their pets live longer, healthier lives. We will do this by tackling one of the leading causes of death and morbidity in both dogs and people- cancer. Our team creates new tests that find cancer early and immunologics that treat or even prevent it.

Digital Screen_TV Loop Slide 7seconds (2).png

2025

StageOne Plus Test

StageOne Plus is the first-ever highly sensitive multi-cancer, multi-stage cancer diagnostic. This new product will be available for dogs at limited clinics.

Learn More

Ongoing

Product Pipeline

Calviri’s product pipeline porfolio focuses on developing breakthrough diagnostics and immunologics. Our strongly research-oriented approach translates innovative science into practical products that redefine how cancer is identified, treated or prevented.

Learn More

Ongoing

Clinical Trials

We strive to not only apply our creativity to products, but to how their clinical trials our conducted. Our innovative trial designs will enable more informative product evaluation and validation, with both less expense and time.

Learn More

StageOne Plus accurately detects the most common canine cancers at stage 1—before signs appear.

StageOne Plus is the first test that can sensitively detect stage 1 cancer, when treatment can save lives.

Pipeline

Calviri is growing a technically and clinically integrated portfolio of first-in-class diagnostics and immunologics to end cancer.

Human Breast Cancer Test for Recurrence

Monitoring Test

Our next product will be a human diagnostic test to monitor women for recurrence of breast cancer post treatment. Prospective sample collections are underway.

A trial is being designed to meet FDA approval guidelines.

H_Br_Stage1_Reoccurance_POC_Pipeline 08.28.25.png

First Ever Preventative Cancer Vaccine Trial

Calviri announced the successful completion of the Vaccine Against Canine Cancer Study (VACCS) on May 4, 2024, followed by the announcement of a one year’s extension. It was a five-year clinical trial investigating a novel preventative cancer vaccine in dogs. This multi-center, double-blinded, placebo-controlled study- the largest of its kind in veterinary oncology- represents a significant milestone in the fight against canine cancer. 

Clinical Trials

Calviri is actively engaged in canine and human clinical trials to evaluate both our preventative and therapeutic vaccines.

Vaccine Against Canine Cancer (VACCS)

Preventative Cancer Trial

We have shown REDNs are strong immunogens and have anti-tumor effects as vaccines in mouse models (Shen et. al. Sci. Rep. 2019). Based on this preclinical demonstration of REDN utility, we used our Discovery chips to select and design a pre-made, REDN vaccine to prevent canine cancer. We initiated a research trial in 2019 with 800+ owner-enrolled dogs. Safety review boards found no side-effects. This trial was scheduled to conclude in May 2024.  However, promising preliminary results led to a year’s extension. Results are being analyzed for publication.  

Canine Hemangiosarcoma (HSA)

Therapeutic Trial

Serum samples from dogs diagnosed with early-stage HSA were collected. These samples were queried on our REDN Discovery chips for optimal components to include in a pre-made, therapeutic vaccine against early-stage disease. REDN’s were identified; vaccine was produced. Vaccinations and clinical monitoring of enrolled dogs are underway.

Human Renal Medullary Cancer (RMC)

Therapeutic Trial

People, especially athletic young men with sickle-cell trait, are predisposed to RMC. Our first-in-man, two-armed trial will enroll those diagnosed with disease, who will receive the therapeutic vaccine and healthy sickle-cell carriers, who will receive a placebo vaccine. Samples have been collected in partnership with collaborators at MD Anderson Cancer Center. These will be evaluated on our REDN Discovery chips to identify RMC-specific neoantigens as components for the vaccine.

Human Neurofibromatosis (NF-1) Pediadric

Therapeutic Trial

Children with a NF-1 genetic condition have a high risk of suffering several different malignant cancers, most frequently gliomas. Our two-armed trial will enroll those diagnosed with pediatric brain cancer, who will receive the therapeutic vaccine and healthy children with the genetic trait, who will receive a placebo vaccine. We have collected samples in collaboration with Children’s National Hospital. These will be evaluated on our REDN Discovery chips to identify NF-1 cancer-specific neoantigens.

Off-The-Shelf Vaccines

Both our preventative and therapeutic vaccines are pre-made and ready to take off the shelves. These vaccines are possible because we have discovered a plentiful source of immunogenic neoantigens that are shared among patient tumors.

Contact Us

Please direct any questions or comments you have for us via our contact form below.

info@calviri.com

850 N. 5th Street Phoenix, AZ

Our Products

StageOne Plus accurately detects the most common canine cancers at stage 1—before signs appear.

StageOne Plus is the first test that can sensitively detect stage 1 cancer, when treatment can save lives.

Pipeline

Our next product will be a human diagnostic test to monitor women for recurrence of breast cancer post treatment. Prospective sample collections are underway.

A trial is being designed to meet FDA approval guidelines.

This vaccine will extend the health-spans and lifespans of dogs diagnosed
with early-stage hemangiosarcoma (HSA).

The canine MCED test, as a companion product, will facilitate identification of early disease.

This vaccine for dogs will significantly reduce cancer incidence and death without side-effects or safety concerns.

Product will be priced to make it affordable in an unreimbursed, animal health market.

The health-spans and lifespans of patients suffering from renal medullary cancer (RMC), typically young adults with sickle cell-trait, will be extended with this vaccine.

Product will be priced to make it affordable worldwide.

An early-stage diagnostic test for the most common cancers in humans is also underway.

The simplicity and low-cost of the test are anticipated to lead to a significant shift in cancer detection from late to early stages, where diagnoses is far more actionable with effective treatments.

An inherited condition called neurofibromatosis type 1 (NF-1) is linked

to the development of several cancers. The health-spans and lifespans of children suffering from NF-1 brain cancer will be extended with this vaccine.

Product will be priced to make it affordable worldwide.

A diagnostic test for stage 1 breast cancer in women will be one of our future products. This simple blood test is anticipated to improve compliance relative to mammography. Since it is inexpensive, confirmatory and interval testing will be practical. Feasibility work is underway.

Clinical Trials

Contact Us

Calviri

Our Products

StageOne Plus accurately detects the most common canine cancers at stage 1—before signs appear.

StageOne Plus is the first test that can sensitively detect stage 1 cancer, when treatment can save lives.

Pipeline

Our next product will be a human diagnostic test to monitor women for recurrence of breast cancer post treatment. Prospective sample collections are underway. A trial is being designed to meet FDA approval guidelines.

Clinical Trials

Contact Us

Calviri

Our next product will be a human diagnostic test to monitor women for recurrence of breast cancer post treatment. Prospective sample collections are underway.

A trial is being designed to meet FDA approval guidelines.